A follow-up phase III trial has to be performed to confirm these findings and assess whether the overall survival benefit is sufficient for clinical implementation.13 Additionally, in the subgroup of glioblastoma patients with a BRAF V600E mutation (∼3%), an objective response rate of 32% with durable clinical benefit was reported after treatment with dabrafenib–trametinib.46 Here, BRAF is linked to glioblastoma.